Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity

Heart Rhythm

Volumn 4, Issue 5, 2007, Pages 629-637

  Xing, Dezhi ^a   Murry, Daryl J ^b   Schmidt, Mark S ^b   Hohl, Raymond J ^a,b   Martins, James B ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Antioxidant; Arrhythmias; Lipid lowering drug; Lovastatin; Myocardial Ischemia; Ventricular tachycardia

Indexed keywords

2,2,6,6 TETRAMETHYLPIPERIDINE 1 OXYL; ANTIOXIDANT; CHLORALOSE; ISOPRENALINE; MEVALONIC ACID; MEVINOLIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG RESPONSE; ELECTROCARDIOGRAPHY; ENDOCARDIUM; FEMALE; HEART DEPOLARIZATION; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART PACING; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; IN VITRO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MICROELECTRODE; NONHUMAN; PRIORITY JOURNAL; REENTRY TACHYCARDIA; THREE DIMENSIONAL IMAGING;

ACTION POTENTIALS; ADRENERGIC BETA-AGONISTS; ANALYSIS OF VARIANCE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIOXIDANTS; BLOOD PRESSURE; BODY SURFACE POTENTIAL MAPPING; CARDIAC PACING, ARTIFICIAL; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; DOGS; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISOPROTERENOL; LOVASTATIN; MALE; MEVALONIC ACID; MICROELECTRODES; MYOCARDIAL ISCHEMIA; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; RESEARCH DESIGN; VENTRICULAR FIBRILLATION;

EID: 34247336883     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2006.12.051     Document Type: Article

References (35)

1. Kannel W.B. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 76 (1995) 69C-77C
2. Lipid Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level. N Engl J Med 339 (1998) 1349-1357
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary disease. Lancet 344 (1994) 1383
4. Stamler J., Wentworth D., and Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?. Findings in 356,222 primary screenees of the Multiple Risk factor Intervention Trial (MRFIT). JAMA 256 (1986) 2823-2828
5. Sacks F.M., Pfeffer M.A., and Moye L.A. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 335 (1996) 1001-1009
6. De Sutter J., Tavernier R., De Buyzere M., Jordaen S.L., and De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 36 (2000) 766-772
7. Mitchell B.L., Powell J.L., Gillis A.M., Kehl V., Hallstrom A.P., and AVID Investigators. Are lipid-lowing drugs also antiarrhythmic drugs?. J Am Coll Cardiol 42 (2003) 81-87
8. Vyas A.K., et al., MADIT-II Research Group. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 769-773
9. Pliquett R.U., Cornish K.G., Peuler J.D., and Zucker I.H. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 107 (2003) 2493-2498
10. Arnar D.O., Xing D., and Martins J.B. Overdrive pacing of early ischemic ventricular tachycardia: evidence for both reentry and triggered activity. Am J Physiol 288 (2005) H1124-H1130
11. Xing D., and Martins J.B. Triggered activity due to delayed afterdepolarizations recorded from sites of origin of ischemic ventricular tachycardia. Am J Physiol 287 (2004) H2078-H2084
12. Arnar D.O., Bullinga J.R., and Martins J.B. Role of the Purkinje system in spontaneous ventricular tachycardia during acute ischemia in a canine model. Circulation 96 (1997) 2421-2429
13. 2-adrenoceptors in Purkinje?. Am J Physiol 280 (2001) H1182-H1190
14. Xing D., Kjolbye A.L., Peterson J.S., and Martins J.B. Pharmacological stimulation of cardiac gap junction coupling does not affect ischemia induced focal ventricular tachycardia or triggered activity in dogs. Am J Physiol 288 (2005) H511-H516
15. Xing D., Kjølbye A.L., Nielsen M.S., Petersen J.S., Harlow K.W., Holstein-Rathlow N.H., and Martins J.B. ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol 14 (2003) 510-520
16. Blankenhorn D.H., Azen S.P., and Kramsch D.M. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis regression Study (MARS). The MARS Research Group. Ann Intern Med 119 (1993) 969-976
17. Brown B.G., and Zhao X.Q. Importance of endothelial function in mediating the benefits of lipid-lowering therapy. Am J Cardiol 82 (1998) 49T-52T
18. Paterick T.E., and Fletcher G.F. Endothelial function and cardiovascular prevention: role of blood lipids, exercise, and other risk factors. Cardiol Rev 9 (2001) 282-286
19. Furst B.A., Champion K.M., Pierre J.M., Wirshing D.A., and Wirshing W.C. Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin. Biol Psychiatry 51 (2002) 264-265
20. Mital S., Zhang X., Zhao G., Bernstein R.D., Smith C.J., Fulton D.L., Sessa W.C., and Liao J.K. Simvastatin regulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol 279 (2000) H2649-H2657
21. Luo J.D., Xie F., Zhang W.W., Ma X.D., Guan J.X., and Chen X. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br J Pharmacol 132 (2001) 159-164
22. Aviram M., Rosenblat M., Bisgaier C., and Newton R. Atorvastatin and gemfibrozil metabolites, but not parent drugs are potent anti-oxidants against lipoprotein oxidation. Atherosclerosis 138 (1998) 271-280
23. Ito K., Hirooka Y., Kimura Y., Shimokawa H., and Takeshita A. Effects of hydroxyfasudil administered to the nucleus tractus solitarii on blood pressure and heart rate in spontaneously hypertensive rats. Clin Exp Hyperten 27 (2005) 269-277
24. ATP channel-induced improvement in postischemic functional recovery. Am J Physiol 288 (2005) H3011-H3015
25. Sugiyama A., Takahara A., Yatomi Y., Satoh Y., Nakamura Y., and Hashimoto K. Constitutional rho-kinase regulates atrioventricular nodal conduction and ventricular repolarization of the canine heart. J Cardiovasc Pharmacol 41 (2003) 930-933
26. ++ currents in cardiac Myocytes. Am J Physiol 288 (2005) H650-H659
27. Xing D., Staley T., Devecchi F., and Martins J. Pharmacological evidence linking focal ischemic ventricular tachycardia in vivo with triggered activity of excised foci in vitro. Biophys J 88 (2005) 300A
28. Gelvan D., Saltman P., and Powell S.R. Cardiac reperfusion damage prevented by a nitroxide free radical. Proc Natl Acad Sci U S A 88 (1991) 4680-4684
29. Chol B.H., Ha K.C., Park J.A., Jung Y.J., Kim J.C., Lee G.I., Chol H.S., Kang Y.J., Chae S.W., and Kwak Y.G. Regional differences of superoxide dismutase activity enhance the super-oxide induced heterogeneity in rabbit hearts. Basic Res Cardiol 100 (2005) 355-364
30. Lamson M., Phillips G., Shen J., Lukacsko P., Friedhoff L., and Niecestro R.M. Pharmacokinetics of lovastatin extended-release dosage form (lovastatin XL) I healthy volunteers. Biopharm Drug Dispos 23 (2002) 143-149
31. Sun J.X., Niecestro R., Phillips G., Shen J., Lukacsko P., and Friedhoff L. Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans. J Clin Pharmacol 42 (2002) 198-204
32. Holstein S.A., Knapp H.R., Clamon G.H., Murry D.J., and Hohl R.J. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 57 (2006) 155-164
33. Bansch D., Oyang F., Antz M., Arentz T., Weber R., Val-Mejias J.E., Ernst S., and Kuck K. Successful catheter ablation of electrical storm after myocardia infarction. Circulation 108 (2003) 3011-3016
34. Szumowski T., Walczk F., Kepski R., Stepinska J., Banaszewski M., Przyblski A., and Szwed H. Role of Purkinje fibers in triggering polymorphic ventricular tachycardia and fibrillation in patient with myocardial infarction. Kardiol Polska 58 (2003) 157-161
35. Haissaguerre M., Shoda M., Jais P., Nogami A., Shah D.C., Kautzner J., Arentz T., Kalushe D., Lamaison D., Griffith M., Cruz F., de Paola A., Gaita F., Hocini M., Garrigue S., Macle L., Weerasooriya R., and Clementy J. Mapping and ablation of idiopathic ventricular fibrillation. Circulation 106 (2002) 962-967